Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Filed Chapter 11
Director departure
Appointed director
Quarterly results
K-V Pharmaceutical Co (KV.A) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/06/2013 8-K Quarterly results
10/18/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "KV Pharmaceutical Company Appoints Two New Board Members ST. LOUIS, Oct. 11, 2013 – K-V Pharmaceutical Company today announced the appointment of two new members to its Board of Directors: Gregory Norden, former Senior Vice President and Chief Financial Officer for Wyeth Corporation, and James M. Goldfarb, MD, MBA, Director of Infertility Services of the University Hospitals of Cleveland Health Systems and Clinical Professor of Reproductive Biology at Case Western Reserve University School of Medicine. “Greg Norden and Dr. Goldfarb’s breadth of knowledge and experience will provide invaluable insight to KV as we continue to grow the business and strive to deliver innovative women’s healthcare products,” said Greg Divis, CEO of KV. Norden and Dr. Goldfarb will join former President of Wyeth..."
10/04/2013 8-K Appointed a new director
Docs: "Non-Employee Director Compensation Policy",
"Form of Option Award Agreement",
"Form of Equity Bonus Agreement",
"KV Pharmaceutical Company Appoints Former Wyeth Pharmaceuticals President, Joe Mahady to Chairman of the Board ST. LOUIS, Oct. 3, 2013 – K-V Pharmaceutical Company today announced the appointment of Joseph M. Mahady as Chairman of its Board of Directors. Previously, Mahady served as Senior Vice President of Wyeth, LLC, and President of Wyeth Pharmaceuticals, Inc., where he led the company’s $20 billion global pharmaceutical business. During his tenure, he oversaw the successful launch of more than 30 products in multiple therapeutic areas. Mahady has held various board positions, including Immunex, Albemarle, EKR Therapeutics, Discovery Labs and Cortendo AB. “Joe’s extensive knowledge and expertise in women’s healthcare will play a critical role in establishing a renewed focus at the compa..."
09/05/2013 8-K Filed for Chapter 11
Docs: "Sixth Amended Joint Chapter 11 Plan of Reorganization for K-V Discovery Solutions, Inc. and Its Affiliated Debtors",
"Order, Confirming Sixth Amended Joint Chapter 11 Plan of Reorganization for K-V Discovery Solutions, Inc. and Its Affiliated Debtors (without exhibits)",
"Share Purchase Agreement, by and among Capital Ventures International, Greywolf Capital Overseas Master Fund, Greywolf Capital Partners II LP, Greywolf Opportunities Fund LLC, Kingdon Associates, Kingdon Credit Master Fund, L.P., Kingdon Family Partnership, L.P., M. Kingdon Offshore Master Fund L.P., Deutsche Bank Securities Inc., Silver Point Finance, LLC and K-V Pharmaceutical Company",
"Second Amended and Restated Stock Purchase and Backstop Agreement, by and among Capital Ventures International, Greywolf Capital Overseas Master Fund, Greywolf Capital Partners II LP, Greywolf Opportunities Fund LLC, Kingdon Associates, Kingdon Credit Master Fund, L.P., Kingdon Family Partnership, L.P., M. Kingdon Offshore Master Fund L.P., Deutsche Bank Securities Inc., Silver Point Finance, LLC and K-V Pharmaceutical Company (without exhibits)",
"Credit and Guaranty Agreement, dated as of [ • ], by and among K-V Pharmaceutical Company, certain subsidiaries of K-V Pharmaceutical Company, as guarantors, the lenders party thereto from time to time and Law Debenture Trust Company of New York, as Administrative Agent and Collateral Agent (substantially final form) (without exhibits)"
08/08/2013 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Ther-Rx Corporation Announces the Availability of Clindesse® Vaginal Cream, 2% for Prescribing"
07/19/2013 8-K Regulation FD Disclosure, Financial Statements and Exhibits
06/27/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "Sixth Amended Joint Chapter 11 Plan of Reorganization for the Debtors",
"Disclosure Statement for Sixth Amended Joint Chapter 11 Plan of Reorganization for the Debtors",
"Share Purchase Agreement, by and among Capital Ventures International, Greywolf Capital Overseas Master Fund, Greywolf Capital Partners II LP, Greywolf Opportunities Fund LLC, Kingdon Associates, Kingdon Credit Master Fund, L.P., Kingdon Family Partnership, L.P., M. Kingdon Offshore Master Fund L.P., Deutsche Bank Securities Inc., Silver Point Finance, LLC and K-V Pharmaceutical Company",
"Stockholders’ Agreement of K-V Pharmaceutical Company, dated [●], 2013"
04/25/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "Second Amended Joint Chapter 11 Plan of Reorganization for the Debtors",
"Disclosure Statement for Second Amended Joint Chapter 11 Plan of Reorganization for the Debtors"
04/19/2013 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Monthly Operating Report for the Period From March 1, 2013 to March 31, 2013"
03/21/2013 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Monthly Operating Report for the Period From February 1, 2013 to February 28, 2013",
"First Amended Joint Chapter 11 Plan of Reorganization for the Debtors",
"Disclosure Statement for First Amended Joint Chapter 11 Plan of Reorganization for the Debtors"
02/20/2013 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Monthly Operating Report for the Period From January 1, 2013 to January 31, 2013"
02/11/2013 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "the potential adverse effects of the Chapter 11 proceedings on the Company’s liquidity or results of operations;"
01/22/2013 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Monthly Operating Report for the Period From December 1, 2012 To December 31, 2012"
01/14/2013 8-K Form 8-K - Current report
01/02/2013 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "K-V Pharmaceutical Receives Court Approval of Hologic Settlement Clears Path Forward for K-V’s Pursuit of Chapter 11 Reorganization Plan St. Louis, MO, December 28, 2012 – K-V Pharmaceutical Company today announced that the U. S. Bankruptcy Court for the Southern District of New York, the Honorable Judge Allan L. Gropper presiding, approved the Company’s settlement agreement with Hologic, Inc. , and authorized the Company to enter into an $85 million debtor-in-possession financing to, among other things, fund the settlement. "The resolution of the Hologic litigation is a major milestone in our restructuring. Now that it is resolved, K-V can focus on completing all other necessary steps for confirmation of a plan of reorganization and timely emergence from Chapter 11,” said K-V President an..."
12/17/2012 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Debtor-In-Possession Credit Agreement, by and among various DIP Lenders and Silver Point Finance, LLC, DIP Agent",
"K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement with Senior Noteholders on Principal Terms of Plan of Reorganization Financing Will Fund Hologic Settlement Agreement, Provide Additional Financial Flexibility During Chapter 11 Proceeding and Fund Payments Under Reorganization Plan St. Louis, MO, December 12, 2012 – K-V Pharmaceutical Company today announced that it has received a commitment from lenders led by an affiliate of Silver Point Finance LLC for $85 million in senior secured post-petition debtor-in-possession financing, which the Company intends to use to, among other things, satisfy the terms of its recently filed settlement agreement with Hologic, Inc. , provide additional financial flexibility during the pendency of the Company’s Chapter 11 proceedi..."
11/27/2012 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Monthly Operating Report for thePeriod from October 1, 2012 toOctober 31, 2012"
10/19/2012 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Monthly Operating Report for the Period from September 1, 2012 to September 30, 2012"
09/26/2012 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Monthly Operating Report for the Period From August 4, 2012 To August 31, 2012"
08/16/2012 8-K Other Events
07/20/2012 8-K Form 8-K - Current report
07/06/2012 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "FDA Issues Further Guidance About Makena ®"
07/03/2012 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
Docs: "K-V Pharmaceutical Company Announces Notification from NYSE Regarding Listing Criteria St. Louis, MO, June 29, 2012 - K-V Pharmaceutical Company today announced that on June 26, 2012 it was notified by the New York Stock Exchange Regulation, Inc., that its Class A common shares is below criteria for the average closing price of a security of less than $1.00 over a consecutive 30 day trading period. This notification pertains to the Class A Common Stock but also affects the Class B Common Stock. The Company will have a six-month period from the date of the NYSE notification to cure this deficiency. Per NYSE procedures, K-V intends to notify the NYSE within 10 business days from the receipt of the NYSE notification of its intent to cure this deficiency within the six-month cure period. Duri..."
06/20/2012 8-K Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
06/07/2012 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Registration Rights Agreement, by and between K-V Pharmaceutical Company and Commerce Court Small Cap Value Fund, Ltd",
"Common Stock Purchase Agreement, by and between K-V Pharmaceutical Company and Commerce Court Small Cap Value Fund, Ltd",
"Engagement Letter, by and between K-V Pharmaceutical Company and Financial West Group"
04/17/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "Materials to be presented at the April 17, 2012 Imperial Capital 2012 Healthcare Investor Forum"
04/04/2012 8-K Form 8-K - Current report
02/13/2012 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "K-V PHARMACEUTICAL ANNOUNCES UPDATED MAKENA ® PERFORMANCE METRICS AND INVESTOR CONFERENCE CALL Company to File Fiscal 2012 Third Quarter 10-Q After the Close of Market Today St. Louis, MO - February 9, 2012 - K-V Pharmaceutical Company today reported updated performance metrics for Makena ® . Makena ® was launched during March of 2011. From its launch date through January 31, 2012:"
01/23/2012 8-K Form 8-K - Current report
12/12/2011 8-K Form 8-K - Current report
11/14/2011 8-K Form 8-K - Current report
10/14/2011 8-K Form 8-K - Current report
09/14/2011 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
08/10/2011 8-K Asset disposition
Docs: "K-V PHARMACEUTICAL COMPANY ANNOUNCES THE COMPLETION OF THE SALE OF NESHER PHARMACEUTICALS, INC. ITS GENERIC PHARMACEUTICAL BUSINESS Divestiture of the Company's Generic Assets Consistent with K-V's Strategic Focus on the Specialty Branded Pharmaceutical Sector St. Louis, MO - August 8, 2011, - K-V Pharmaceutical Company today announced the completion and closing of the previously announced sale of assets of Nesher Pharmaceuticals, Inc. , the Company's wholly-owned generic subsidiary, and the Company's generic business and assets to Zydus Pharmaceuticals , Inc and Zynesher Pharmaceuticals LLC . The aggregate sales price for the transaction is $60 million of which $7.5 million will be held in an escrow arrangement for post-closing indemnification purposes. The purchase includes the physical..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy